Buckley C E, White D H, Seigler H F
Monogr Allergy. 1977;11:97-105.
Cutaneous responses to tuberculin and control antigens were measured in 24 HLA-B7 and 39 non-B7 patients before and 5-44 (average 10.5) weeks after BCG immunotherapy for malignant melanoma. Delayed tuberculin hypersensitivity increased after immunotherapy (p less than or equal 0.0001). The averaged area of induration (48 h) detected in HLA-B7 patients was half the area of induration of non-B7 patients before (p less than or equal to 0.0184) and after (p less than or equal to 0.0007) BCG treatment. Cutaneous anaphylactic hypersensitivity (0.25 h) responses to 19 of 22 antigens were significantly smaller (p less than 0.05) in HLA-B7 patients after BCG immunotherapy (p less than or equal to 0.0001). HLA-B7 patients had specific delayed cutaneous hyporesponsiveness to tuberculin and nonspecific cutaneous anaphylactic hyporesponsiveness after BCG immunotherapy.
在24例HLA - B7患者和39例非B7患者中，于卡介苗免疫治疗恶性黑色素瘤之前以及治疗后5 - 44周（平均10.5周）测量了对结核菌素和对照抗原的皮肤反应。免疫治疗后迟发型结核菌素超敏反应增强（p小于或等于0.0001）。在卡介苗治疗前（p小于或等于0.0184）和治疗后（p小于或等于0.0007），HLA - B7患者检测到的平均硬结面积（48小时）是非B7患者硬结面积的一半。卡介苗免疫治疗后，HLA - B7患者对22种抗原中的19种的皮肤过敏超敏反应（0.25小时）显著较小（p小于0.05）（p小于或等于0.0001）。HLA - B7患者在卡介苗免疫治疗后对结核菌素具有特异性迟发型皮肤低反应性，对皮肤过敏具有非特异性皮肤低反应性。
